Responses to the #COVID-19 outbreak from Oncologists, Cancer Societies and the NCI: Important information for cancer patients
Curator: Stephen J. Williams, Ph.D.
UPDATED 3/20/2020
Among the people who are identified at risk of coronovirus 2019 infection and complications of the virus include cancer patients undergoing chemotherapy, who in general, can be immunosuppressed, especially while patients are undergoing their treatment. This has created anxiety among many cancer patients as well as their care givers and prompted many oncologist professional groups, cancer societies, and cancer centers to formulate some sort of guidelines for both the cancer patients and the oncology professional with respect to limiting the risk of infection to coronavirus (COVID19).
This information will be periodically updated and we are working to get a Live Twitter Feed to bring oncologist and cancer patient advocacy groups together so up to date information can be communicated rapidly. Please see this page regularly for updates as new information is curated.
IN ADDITION, I will curate a listing of drugs with adverse events of immunosuppression for people who might wonder if the medications they are taking are raising their risk of infections.
Please also see @pharma_BI for updates as well.
Please also see our Coronavirus Portal at https://pharmaceuticalintelligence.com/coronavirus-portal/
For ease of reading information for patients are BOLDED and in RED
From the Cancer Letter: The following is a guest editorial by American Society of Clinical Oncology (ASCO) Executive Vice President and Chief Medical Officer Richard L. Schilsky MD, FACP, FSCT, FASCO. This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.
The worldwide spread of the coronavirus (COVID-19) presents unprecedented challenges to the cancer care delivery system.
Our patients are already dealing with a life-threatening illness and are particularly vulnerable to this viral infection, which can be even more deadly for them. Further, as restrictions in daily movement and social distancing take hold, vulnerable patients may be disconnected from friends, family or other support they need as they manage their cancer.
As providers, we rely on evidence and experience when treating patients but now we face uncertainty. There are limited data to guide us in the specific management of cancer patients confronting COVID-19 and, at present, we have no population-level guidance regarding acceptable or appropriate adjustments of treatment and practice operations that both ensure the best outcome for our patients and protect the safety of our colleagues and staff.
As normal life is dramatically changed, we are all feeling anxious about the extreme economic challenges we face, but these issues are perhaps even more difficult for our patients, many of whom are now facing interruption
As we confront this extraordinary situation, the health and safety of members, staff, and individuals with cancer—in fact, the entire cancer community—is ASCO’s highest priority.
ASCO has been actively monitoring and responding to the pandemic to ensure that accurate information is readily available to clinicians and their patients. Recognizing that this is a rapidly evolving situation and that limited oncology-specific, evidence-based information is available, we are committed to sharing what is known and acknowledging what is unknown so that the most informed decisions can be made.
To help guide oncology professionals as they deal with the impact of coronavirus on both their patients and staff, ASCO has collated questions from its members, posted responses at asco.org and assembled a compendium of additional resources we hope will be helpful as the virus spreads and the disease unfolds. We continue to receive additional questions regarding clinical care and we are updating our FAQs on a regular basis.
We hope this information is helpful even when it merely confirms that there are no certain answers to many questions. Our answers are based on the best available information we identify in the literature, guidance from public health authorities, and input received from oncology and infectious disease experts.
For patients, we have posted a blog by Dr. Merry Jennifer Markham, chair of ASCO’s Cancer Communications Committee. This can be found on Cancer.Net, ASCO’s patient information website, and it provides practical guidance to help patients reduce their risk of exposure, better understand COVID-19 symptoms, and locate additional information.
This blog is available both in English and Spanish. Additional blog posts addressing patient questions will be posted as new questions are received and new information becomes available.
Find below a Tweet from Dr.Markham which includes links to her article on COVID-19 for cancer patients
https://twitter.com/DrMarkham/status/1237797251038220289?s=20
NCCN’s Response to COVID-19 and COVID-19 Resources
JNCCN: How to Manage Cancer Care during COVID-19 Pandemic
Experts from the Seattle Cancer Care Alliance (SCCA)—a Member Institution of the National Comprehensive Cancer Network® (NCCN®)—are sharing insights and advice on how to continue providing optimal cancer care during the novel coronavirus (COVID-19) pandemic. SCCA includes the Fred Hutchinson Cancer Research Center and the University of Washington, which are located in the epicenter of the COVID-19 outbreak in the United States. The peer-reviewed article sharing best practices is available for free online-ahead-of-print via open access at JNCCN.org.
Coronavirus disease 2019 (COVID-19) Resources for the Cancer Care Community
NCCN recognizes the rapidly changing medical information relating to COVID-19 in the oncology ecosystem, but understands that a forum for sharing best practices and specific institutional responses may be helpful to others. Therefore, we are expeditiously providing documents and recommendations developed by NCCN Member Institutions or Guideline Panels as resources for oncology care providers. These resources have not been developed or reviewed by the standard NCCN processes, and are provided for information purposes only. We will post more resources as they become available so check back for additional updates.
Documents
- UCSF_COVID-19 Self Screen Signs All Translations 3.2.20
- HCI_COVID19_visitor_policy_letter
- HCI_COVID19_cancer_patients_factsheet
- MGH_COVID19_early_melanoma_patients_3.17.20
Links
- More information from SCCA: https://www.seattlecca.org/covid-19-screening-tools
- More information from Huntsman Cancer Institute at the University of Utah: https://healthcare.utah.edu/coronavirus
National Cancer Institute Response to COVID-19
More information at https://www.cancer.gov/contact/emergency-preparedness/coronavirus
What people with cancer should know: https://www.cancer.gov/coronavirus
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
Coronavirus: What People with Cancer Should Know
- What is coronavirus, or COVID-19?
- If I have cancer, am I at higher risk of getting or dying from COVID-19?
- If I have cancer, how can I protect myself?
- I receive cancer treatment at a medical facility. What should I do about getting treatment?
- I participate in a clinical trial at a medical facility. What should I do?
- What should I do if I have symptoms of an infection?
Both the resources at cancer.gov (NCI) as well as the resources from ASCO are updated as new information is evaluated and more guidelines are formulated by members of the oncologist and cancer care community and are excellent resources for those living with cancer, and also those who either care for cancer patients or their family and relatives.
Related Resources for Patients (please click on links)
Some resources and information for cancer patients from Twitter
Twitter feeds which may be useful sources of discussion and for cancer patients include:
@OncLive OncLive.com includes healthcare information for patients and includes videos and newsletters
@DrMarkham Dr. Markham is Chief of Heme-Onc & gyn med onc @UF | AD Med Affairs @UFHealthCancer and has collected very good information for patients concerning #Covid19
@DrMaurieMarkman Dr. Maurie Markman is President of Medicine and Science (Cancer Centers of America, Philadelphia) @CancerCenter #TreatThePerson #Oncology #Genomics #PrecisionMedicine and hosts a great online live Tweet feed discussing current topics in cancer treatment and care for patients called #TreatThePerson Chat
UPDATED 3/20/2020 INFORMATION FROM NCI DESIGNATED CANCER CENTERS FOR PATIENTS/PROVIDERS
The following is a listing with links of NCI Designated Comprehensive Cancer Centers and some select designated Cancer Centers* which have information on infectious risk guidance for cancer patients as well as their physicians and caregivers. There are 51 NCI Comprehensive Cancer Centers and as more cancer centers formulate guidance this list will be updated.
Cancer Center | State | Link to COVID19 guidance |
City of Hope | CA | Advice for cancer patients, survivors and caregivers |
Jonsson Cancer Center at UCLA | CA | Cancer and COVID19 |
UCSF Hellen Diller Family Comprehensive Cancer | CA | COVID-19 Links for Patients and Providers |
Lee Moffit | FL | Protecting against Coronavirus 19 |
University of Kansas Cancer Center* | KS | COVID19 Info for patients |
Barbara & Karmanos Cancer Institute (Wayne State) | MI | COVID19 Resources |
Rogel Cancer Center (Univ of Michigan) | MI | COVID19 Patient Specific Guidelines |
Alvin J. Siteman Cancer Center | (MO) | Coronavirus |
Fred & Pamela Buffet CC* | NE | Resources for Patients and Providers |
Rutgers Cancer Institute of NJ | NJ | What patients should know about COVID19 |
Memorial Sloan Kettering | NY | What COVID19 means for cancer patients |
Herbert Irving CC (Columbia University) | NY | Coronavirus Resource Center |
MD Anderson Cancer | TX | Planning for Patients, Providers |
Hunstman Cancer Center | UT | COVID19 What you need to know |
Fred Hutchinson | WA | COVID19 What patients need to know |
Please also see related information on Coronavirus 2019 and Cancer and Immunotherapy at the following links on the Open Access Online Journal:
Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
at
https://pharmaceuticalintelligence.com/biomed-e-books/series-c-e-books-on-cancer-oncology/volume-two-immunotherapy-in-cancer-radiation-oncology/
AND
Coronavirus Portal
Leave a Reply